Published in World J Gastroenterol on February 07, 2010
Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol (2012) 1.29
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.09
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver (2011) 0.99
Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn Mag (2011) 0.92
Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol (2014) 0.90
Irritable bowel syndrome. BMJ Clin Evid (2012) 0.87
Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2014) 0.84
Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.84
Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil (2013) 0.83
Are probiotics effective in management of irritable bowel syndrome? Arch Med Sci (2012) 0.80
Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol (2014) 0.80
Treatment of irritable bowel syndrome in China: a review. World J Gastroenterol (2015) 0.80
Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol (2011) 0.79
Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Arch Med Sci (2014) 0.79
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Biomed Res Int (2014) 0.78
Irritable bowel syndrome: a review article. Middle East J Dig Dis (2010) 0.78
A preliminary evaluation of comparative effectiveness of riluzole in therapeutic regimen for irritable bowel syndrome. Asian Pac J Trop Biomed (2014) 0.76
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology (2015) 0.75
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol (2015) 0.75
Is Otilonium Bromide Really Effective for Treating Asian Patients With Irritable Bowel Syndrome?: Author's Reply. J Neurogastroenterol Motil (2012) 0.75
Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104). J Neurogastroenterol Motil (2012) 0.75
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther (2003) 3.41
The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil (2005) 2.11
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2008) 2.04
Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol (2009) 1.44
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci (2007) 1.27
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther (1999) 1.21
Comparison of various treatments for irritable bowel syndrome. Br Med J (1980) 1.20
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther (2008) 1.13
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (1994) 1.12
Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol (2000) 1.08
Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J (1965) 1.07
Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion (1986) 0.98
Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J (1973) 0.96
Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care (2001) 0.90
Pathogenesis and management of irritable bowel syndrome. Trop Gastroenterol (2009) 0.89
[Determination of placebo effect in irritable bowel syndrome]. Dtsch Med Wochenschr (2005) 0.87
Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther (2006) 0.86
A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin (1980) 0.84
The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner (1983) 0.83
Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med (1972) 0.83
A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther (1995) 0.82
[The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome]. Fortschr Med (1978) 0.80
Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract (2000) 0.79
[Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon]. Minerva Med (1983) 0.79
A systematic review of aluminium phosphide poisoning. Arh Hig Rada Toksikol (2012) 2.93
A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother (2005) 2.84
Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries. Daru (2013) 2.56
Poison treatment centers in Iran. Hum Exp Toxicol (2010) 2.47
Perspectives of science in iran. Iran J Pharm Res (2010) 2.40
Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights (2005) 2.36
Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (2007) 2.28
Pesticides and oxidative stress: a review. Med Sci Monit (2004) 2.16
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2008) 2.04
A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol (2009) 1.90
Factors related to seizure in tramadol poisoning and its blood concentration. J Med Toxicol (2011) 1.87
A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets (2009) 1.83
Science growth in Iran over the past 35 years. J Res Med Sci (2012) 1.73
Successful treatment of acute aluminium phosphide poisoning: possible benefit of coconut oil. Hum Exp Toxicol (2005) 1.61
A meta-analysis on the efficacy and safety of combined vitamin C and E supplementation in preeclamptic women. Hypertens Pregnancy (2009) 1.61
Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol Appl Pharmacol (2013) 1.53
Pattern of acute poisoning in Tehran-Iran in 2003. Hum Exp Toxicol (2007) 1.52
Pesticides and human chronic diseases: evidences, mechanisms, and perspectives. Toxicol Appl Pharmacol (2013) 1.52
Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol (2009) 1.44
Pharmaceutical supply chain risks: a systematic review. Daru (2013) 1.44
Observance of ethical codes in selecting supervisor by postgraduate students. J Med Ethics Hist Med (2011) 1.44
A review on delayed toxic effects of sulfur mustard in Iranian veterans. Daru (2012) 1.43
Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial. Evid Based Complement Alternat Med (2008) 1.38
Toxic influence of organophosphate, carbamate, and organochlorine pesticides on cellular metabolism of lipids, proteins, and carbohydrates: a systematic review. Hum Exp Toxicol (2010) 1.36
Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study. Daru (2012) 1.35
Patterns of antibiotic consumption in Iran during 2000-2009. Int J Antimicrob Agents (2011) 1.34
Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions. Arch Med Sci (2011) 1.30
Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol (2012) 1.29
Methemoglobinemia in aluminum phosphide poisoning. Hum Exp Toxicol (2010) 1.27
A systematic review on status of lead pollution and toxicity in Iran; Guidance for preventive measures. Daru (2012) 1.27
Current opinion on the science of organophosphate pesticides and toxic stress: a systematic review. Med Sci Monit (2009) 1.26
A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci (2008) 1.26
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol (2002) 1.25
A model for developing a decision support system to simulate national drug policy indicators. Arch Med Sci (2011) 1.25
The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr Pharm Des (2010) 1.24
A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit (2008) 1.23
On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci (2008) 1.22
Dose-independent occurrence of seizure with tramadol. J Med Toxicol (2009) 1.21
Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res (2005) 1.21
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol (2010) 1.20
Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum Exp Toxicol (2005) 1.19
Investigating Two Different Training Time Frames during Ramadan Fasting. Asian J Sports Med (2011) 1.18
The performance of loghman-hakim drug and poison information center from 2006 to 2008. Iran J Pharm Res (2011) 1.16
Investigation of the possible biological activities of a poisonous South African plant; Hyaenanche globosa (Euphorbiaceae). Pharmacogn Mag (2010) 1.15
Antinociceptive effects of the essential oil of Dracocephalum kotschyi in the mouse writhing test. J Pharm Pharm Sci (2004) 1.15
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther (2008) 1.13
Antidiabetic effect of Phlomis anisodonta: effects on hepatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Pharmacol Res (2007) 1.13
Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol (2007) 1.12
Methods for the discovery of new anti-aging products--targeted approaches. Expert Opin Drug Discov (2014) 1.11
Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease. Evid Based Complement Alternat Med (2006) 1.11
Benefits of magnesium sulfate in the management of acute human poisoning by organophosphorus insecticides. Hum Exp Toxicol (2004) 1.11
Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum Exp Toxicol (2006) 1.11
The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Dordr) (2009) 1.11
Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol (2005) 1.10
The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci (2010) 1.10
A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther (2006) 1.10
Study of drug-drug interactions in prescriptions of general practitioners and specialists in iran 2007-2009. Iran J Pharm Res (2011) 1.08
Current opinion on nanotoxicology. Daru (2012) 1.08
Effect of Satureja khuzestanica essential oil on male rat fertility. Fitoterapia (2006) 1.08
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol (2003) 1.08
Consequences of international sanctions on Iranian scientists and the basis of science. Hepat Mon (2013) 1.07
Biochemical and histopathological evidences for beneficial effects of satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods (2006) 1.06
Report of methamphetamine use and cardiomyopathy in three patients. Daru (2012) 1.06
Antioxidant Activity of Iranian Echium amoenum Fisch & C.A. Mey Flower Decoction in Humans: A cross-sectional Before/After Clinical Trial. Evid Based Complement Alternat Med (2006) 1.06
Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J Biochem Biophys (2010) 1.05
Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.04
On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci (2007) 1.04
Biochemical and ultrastructural evidences for toxicity of lead through free radicals in rat brain. Hum Exp Toxicol (2003) 1.04
Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century. Toxicol Appl Pharmacol (2013) 1.04
Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin Toxicol (Phila) (2012) 1.04
Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol (2006) 1.03
Synthesis and analgesic activity of N-Arylhydrazone derivatives of mefenamic acid. J Pharm Pharm Sci (2005) 1.03
Oxidative stress in acute human poisoning with organophosphorus insecticides; a case control study. Environ Toxicol Pharmacol (2004) 1.03
Study on clinical and biochemical toxicity biomarkers in a zinc-lead mine workers. Toxicol Ind Health (2010) 1.03
Different biokinetics of nanomedicines linking to their toxicity; an overview. Daru (2013) 1.02
A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets (2012) 1.02
Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer. Arch Med Sci (2013) 1.02
Effect of chicory seed extract on glucose tolerance test (GTT) and metabolic profile in early and late stage diabetic rats. Daru (2012) 1.01